Constitution of a system of microarray CGH analysis for wide-screening and a research for genes responsible for hepatocellular carcinoma

HBVDNA整合在人DNA的任意位置，MLL2基因是整合的靶点之一。我们的结果提示，在肝癌的发生过程中，HBVDNA可能调控整合位点附近的人类基因，进而调节这些基因的整合位点特异性表达。采用RT-PCR方法检测高迁移率族A2(HMGA2)在肝细胞癌组织和非癌组织中的表达和变化。在三分之一的癌组织中发现了该基因的表达，在分化较低的癌组织中该基因的表达增加。这种交替在低分化肝细胞癌中也增加。结果表明，HMGA2的表达和改变与肝细胞癌的发生发展密切相关。尽管肿瘤直径>5 cm的门静脉主干癌栓患者血清细胞角蛋白-19片段(Cyfra 21-1)浓度较高，但由于其敏感性较低，不能作为诊断肝细胞癌的有用工具。在肝细胞癌切除患者中，干扰素治疗有效的患者的结果优于治疗无效或无效的患者。干扰素治疗可以改善肝硬变患者的术后预后，特别是在干扰素治疗控制了活动性肝炎的情况下，可以抑制复发和预防预后。

HBV DNA was integrated at random sites of human DNA, and the MLL2 gene was cone of the targets for integration. Our results suggest that HBV DNA might modulate human genes near integration sites, followed by integration site - specific expression of such genes during hepatocarcinogenesis.The expression and alternation of high mobility group A2 (HMGA2) were investigated by RT-PCR using cancerous tissues and noncancerous tissues in patients with hepatocellular carcinoma. The expression was found in one-third of cancerous tissues and the prevalence increased in less differentiated carcinoma. The alternation also increased in poorly differentiated hepatocellular carcinoma. The results indicate the expression and alternation of HMGA2 correlated with the development of hepatocellular carcinoma.Although high concentration of serum cytokeratin-19 fragment (CYFRA 21-1) were often detected in patients with a tumor diameter greater than 5 cm of tumor thrombus in the major portal vein, CYFRA 21\1 is not a useful diagnostic tool for hepatocellular carcinoma because of its low sensitivity.In patients who underwent liver resection for hepatocellular carcinoma, the results were superior in patients who respond interferon therapy than in patients who did not respond the therapy or who lacks the therapy. Interferon therapy can improve postoperative outcomes because of suppression of recurrence and preventing prognosis of cirrhosis, especially when interferon therapy has controlled their active hepatitis.